KRAS codon 12 and 13 mutations in metastatic colorectal cancer: Predictive marker in first-line bevacizumab-based chemotherapy

被引：0
|
作者：
Cunha Pereira, T. [1 ]
Salgueiro, F. [1 ]
Monteiro, A. [1 ]
Felix Soares, R. [1 ]
Macedo, F. [1 ]
Jacinto, P. [1 ]
Paulo, J. [1 ]
Bonito, N. [1 ]
Marques, M. [1 ]
Ribeiro, J. [1 ]
Sousa, G. [1 ]
机构：
[1] Portuguese Oncol Inst Coimbra Francisco Gentil, Coimbra, Portugal
来源：
ANNALS OF ONCOLOGY | 2020年 / 31卷
关键词：
D O I：
10.1016/j.annonc.2020.04.307
中图分类号：
R73 [肿瘤学];
学科分类号：
100214 ;
摘要：
P-225
引用
收藏
页码：S163 / S164
页数：2
相关论文
共 50 条
  • [41] Chemotherapy plus bevacizumab versus chemotherapy plus cetuximab as first-line treatment for patients with metastatic colorectal cancer
    Bai, Long
    Wang, Feng
    Li, Zhe-zhen
    Ren, Chao
    Zhang, Dong-sheng
    Zhao, Qi
    Lu, Yun-xin
    Wang, De-shen
    Ju, Huai-qiang
    Qiu, Miao-zhen
    Wang, Zhi-qiang
    Wang, Feng-hua
    Xu, Rui-hua
    MEDICINE, 2016, 95 (51) : e4531
  • [42] Existing anti-angiogenic therapeutic strategies for patients with metastatic colorectal cancer progressing following first-line bevacizumab-based therapy
    Kanat, Ozkan
    Ertas, Hulya
    WORLD JOURNAL OF CLINICAL ONCOLOGY, 2019, 10 (02): : 52 - 61
  • [43] Progression-Free Survival in Bevacizumab-Based First-Line Treatment for Patients With Metastatic Colorectal Cancer: Is It a Really Good End Point?
    Montagnani, Francesco
    Migali, Cristina
    Fiorentini, Giammaria
    JOURNAL OF CLINICAL ONCOLOGY, 2009, 27 (28) : E132 - E133
  • [44] KRAS mutation status to predict response in first-line capox and bevacizumab therapy for metastatic colorectal cancer.
    Yone, You
    Abdallah, Mohammad
    Tahir, Saad Sabih
    Cellek, Selim
    Zhang, Jufen
    Lester, Yvonne
    Shillito, Lauren
    Child, Jennifer
    Dawson, Lizzie
    Singizi, Bryan
    Bustin, Stephen
    JOURNAL OF CLINICAL ONCOLOGY, 2019, 37 (04)
  • [45] Efficacy and safety of bevacizumab with standard first-line fluoropyrimidine-based chemotherapy in patients with metastatic colorectal cancer: First beat
    Rivera, F.
    Cunningham, D.
    Berry, S.
    Kretzschmar, A.
    Michael, M.
    Dibartolomeo, M.
    Mazier, M.
    Andre, N.
    Van Cutsem, E.
    ANNALS OF ONCOLOGY, 2008, 19 : 17 - 17
  • [46] Cetuximab-based or bevacizumab-based first-line treatment in patients with KRAS p. G13D mutated metastatic colorectal cancer (mCRC)? A meta-analysis of 54 cases.
    Heinemann, Volker
    Reinacher-Schick, Anke
    Stintzing, Sebastian
    Giessen, Clemens Albrecht
    Tannapfel, Andrea
    Laubender, Ruediger P.
    Brodowicz, Thomas
    Knittelfelder, Regina
    Vrbanec, Damir
    Schmiegel, Wolff
    Modest, Dominik Paul
    Zielinski, Christoph
    JOURNAL OF CLINICAL ONCOLOGY, 2012, 30 (04)
  • [47] Pre-treatment lactate dehydrogenase levels as predictor of efficacy of first-line bevacizumab-based therapy in metastatic colorectal cancer patients
    M Scartozzi
    R Giampieri
    E Maccaroni
    M Del Prete
    L Faloppi
    M Bianconi
    E Galizia
    C Loretelli
    L Belvederesi
    A Bittoni
    S Cascinu
    British Journal of Cancer, 2012, 106 : 799 - 804
  • [48] SAFETY AND EFFICACY OF BEVACIZUMAB PLUS STANDARD FIRST-LINE CHEMOTHERAPY IN PATIENTS WITH METASTATIC COLORECTAL CANCER: FIRST BEAT
    Van Cutsem, E.
    Berry, S.
    Michael, M.
    Kretzschmar, A.
    Rivera, F.
    DiBartolomeo, M.
    Mazier, M.
    Andre, N.
    Cunningham, D.
    ANNALS OF ONCOLOGY, 2008, 19 : 125 - 125
  • [49] KRAS status and clinical outcome in metastatic colorectal cancer patients treated with first-line FOLFOX chemotherapy
    Sharma, Neelesh
    Saifo, Maher
    Tamaskar, Ila R.
    Bhuvaneswari, Ramkumar
    Mashtare, Terry
    Fakih, Marwan
    JOURNAL OF GASTROINTESTINAL ONCOLOGY, 2010, 1 (02) : 90 - 96
  • [50] Circulating endothelial cells predict for response to bevacizumab-based chemotherapy in metastatic colorectal cancer
    Satoshi Matsusaka
    Mitsukuni Suenaga
    Yuji Mishima
    Koichi Takagi
    Yasuhito Terui
    Nobuyuki Mizunuma
    Kiyohiko Hatake
    Cancer Chemotherapy and Pharmacology, 2011, 68 : 763 - 768
12345